Please note that, following on from information provided to NICE by the company in July 2011, the appraisal of Pegaptanib sodium for the treatment of diabetic macular oedema [ID452] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Decision | Selected |
| Process | TA |
| Referral date | 01 March 2011 |
| Topic area |
|
| Description |
NICE has been informed by the manufacturer of Pegaptanib, Pfizer, that they have withdrawn their licensing application for the above indication. Therefore this appraisal topic has been suspended and the appraisal committee agenda topic that was due to take place on 8 November 2011 has been cancelled. Scoped within Batch 16 |
Provisional Schedule
| Closing date for invited submissions / evidence submission: | TBC |
| 1st appraisal committee meeting: | TBC |
Project Team
| Communications manager: | Alice Law |
| Executive Lead: | TBC |
| Project manager: | Lori Farrar |
| Technical Lead: | Helen Tucker |
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 20 January 2023 | Discontinued. Please note that, following on from information provided to NICE by the company in July 2011, the appraisal of Pegaptanib sodium for the treatment of diabetic macular oedema [ID452] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 29 July 2011 |
NICE has been informed by the manufacturer of Pegaptanib, Pfizer, that they have withdrawn their licensing application for the above indication. Therefore this appraisal topic has been suspended and the appraisal committee agenda topic that was due to take place on 8 November 2011 has been cancelled. NICE will continue to monitor any development and update this webpage if the situation changes. |
For further information on our processes and methods, please see our CHTE processes and methods manual